9-ING-41 in Pediatric Patients With Refractory Malignancies.
Conditions: Refractory Cancer; Refractory Neoplasm; Cancer Pediatric; Refractory Tumor; Pediatric Cancer; Pediatric Brain Tumor; Neuroblastoma; Neuroblastoma Recurrent; Pediatric Lymphoma; Pediatric Meningioma Interventions: Drug: 9-ING-41; Drug: Irinotecan Sponsors: Actuate Therapeutics Inc.; Developmental Therapeutics Consortium Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Brain | Cancer | Cancer & Oncology | Lymphoma | Men | Neuroblastoma | Neurology | Pediatrics | Research